JP2010512414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512414A5 JP2010512414A5 JP2009541511A JP2009541511A JP2010512414A5 JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5 JP 2009541511 A JP2009541511 A JP 2009541511A JP 2009541511 A JP2009541511 A JP 2009541511A JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- subject
- baseline
- ambrisentan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 8
- 229960002414 ambrisentan Drugs 0.000 claims 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 230000000386 athletic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002250 eicosanoid group Chemical group 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86966706P | 2006-12-12 | 2006-12-12 | |
| PCT/US2007/087058 WO2008073928A1 (en) | 2006-12-12 | 2007-12-11 | Composition for treating a pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512414A JP2010512414A (ja) | 2010-04-22 |
| JP2010512414A5 true JP2010512414A5 (enExample) | 2011-02-03 |
Family
ID=39092031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541511A Withdrawn JP2010512414A (ja) | 2006-12-12 | 2007-12-11 | 肺高血圧を処置するための組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US20080139593A1 (enExample) |
| EP (2) | EP2952193A1 (enExample) |
| JP (1) | JP2010512414A (enExample) |
| AU (1) | AU2007333115B2 (enExample) |
| CA (1) | CA2669536C (enExample) |
| CY (1) | CY2016017I2 (enExample) |
| DK (1) | DK2101777T3 (enExample) |
| ES (1) | ES2544724T3 (enExample) |
| HK (1) | HK1218393A1 (enExample) |
| HU (2) | HUE025355T2 (enExample) |
| LU (1) | LU93081I2 (enExample) |
| PL (1) | PL2101777T3 (enExample) |
| PT (1) | PT2101777E (enExample) |
| SI (1) | SI2101777T1 (enExample) |
| WO (1) | WO2008073928A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2544724T3 (es) | 2006-12-12 | 2015-09-03 | Gilead Sciences, Inc. | Composición para tratar una hipertensión pulmonar |
| CA2693400A1 (en) * | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| WO2010062640A1 (en) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| KR20130088834A (ko) * | 2010-06-30 | 2013-08-08 | 길리애드 사이언시즈, 인코포레이티드 | 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도 |
| ES2627944T3 (es) | 2010-10-15 | 2017-08-01 | Gilead Sciences, Inc. | Composiciones y métodos de tratamiento de hipertensión pulmonar |
| EP2741777B1 (en) * | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
| US20130224306A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating a pulmonary hypertension condition without companion diagnosis |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2015193889A1 (en) * | 2014-06-18 | 2015-12-23 | Sonivie Ltd. | Method for treating secondary pulmonary hypertension |
| US10576083B2 (en) * | 2015-08-13 | 2020-03-03 | Cipla (UK) Limited | Method of treating pulmonary arterial hypertension |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| SG11202000893QA (en) * | 2017-08-30 | 2020-02-27 | Bellerophon Pulse Tech Llc | Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease |
| EA202091286A1 (ru) * | 2017-12-28 | 2020-11-05 | Беллерофон Пульс Текнолоджис Ллс | Применение вдыхаемого оксида азота (ii) и кислорода для лечения легочной гипертензии |
| EP3965767A1 (en) * | 2019-05-06 | 2022-03-16 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
| RU2729033C1 (ru) * | 2020-02-03 | 2020-08-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| EP3906928A1 (en) * | 2020-05-06 | 2021-11-10 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus |
| CN114324900A (zh) * | 2021-12-03 | 2022-04-12 | 上海市肺科医院 | 一种促卵泡激素的应用 |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
| AU2024207876A1 (en) * | 2023-01-09 | 2025-07-31 | Scpharmaceuticals Inc. | Methods of treatment using loop diuretics |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4325525A (en) | 1980-11-13 | 1982-04-20 | General Motors Corporation | Mounting member |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DK1174431T3 (da) | 1997-11-12 | 2012-08-20 | Bayer Pharma AG | 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2006007213A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| TW200621261A (en) | 2004-08-26 | 2006-07-01 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| WO2006081289A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| SI2013208T1 (sl) * | 2006-04-21 | 2011-09-30 | Pfizer Prod Inc | Piridin(3,4-b)pirazinoni |
| EP2091539A1 (en) * | 2006-12-12 | 2009-08-26 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
| ES2544724T3 (es) * | 2006-12-12 | 2015-09-03 | Gilead Sciences, Inc. | Composición para tratar una hipertensión pulmonar |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| ES2627944T3 (es) | 2010-10-15 | 2017-08-01 | Gilead Sciences, Inc. | Composiciones y métodos de tratamiento de hipertensión pulmonar |
-
2007
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/en not_active Withdrawn
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 CA CA2669536A patent/CA2669536C/en active Active
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/en unknown
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/en not_active Ceased
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/en not_active Revoked
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
-
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
-
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
-
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
-
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
-
2016
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/en unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010512414A5 (enExample) | ||
| Korn et al. | Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist | |
| AU2013299625B2 (en) | Treatment of immune-related and inflammatory diseases | |
| Wang et al. | The role of aldosterone in OSA and OSA-related hypertension | |
| Karlberg et al. | Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension | |
| Croom et al. | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy | |
| Eguchi et al. | Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
| JP2011515349A5 (enExample) | ||
| Balakumar et al. | Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated | |
| Melian et al. | Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension | |
| JP2003519228A5 (enExample) | ||
| US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
| JP2009518415A5 (enExample) | ||
| JP2013528649A5 (enExample) | ||
| JP2018502126A5 (enExample) | ||
| Destro et al. | Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring | |
| Spinar et al. | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study) | |
| Lacourcière et al. | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension | |
| Fogari et al. | Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study | |
| AU2006311574A1 (en) | Use of cicletanine and other furopyridines for treatment of hypertension | |
| JP4702054B2 (ja) | 増強剤 | |
| Wenzel et al. | Treatment of Arterial Hypertension | |
| AU2015305430A1 (en) | Method for treating hyperhidrosis |